Jump to content

Update

From Neoplasm
Revision as of 13:53, 31 December 2025 by Qiangnai (talk | contribs) (Created page with "<includeonly> {| class="wikitable neoplasm-table" ! Approval date ! Medication (Brand) ! Company ! Indication ! Regulatory type ! Trial(s) cited on FDA approval page |- | 2025-07-02 | Sunvozertinib (Zegfrovy) | Dizal Pharma | EGFR exon 20 insertion NSCLC after platinum therapy | Accelerated approval | WU-KONG1 |- | 2025-07-02 | Linvoseltamab-gcpt (Lynozyfic) | Regeneron | Relapsed/refractory multiple myeloma (≥4 prior lines) | Accelerated approval | LINKER-MM1...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

This template lists FDA oncology approvals in 2025. Trials are those explicitly cited on FDA approval pages.

Retrieved from "https://neoplasm.org/index.php?title=Update&oldid=101"